What types of proteases can be used in the screening process?

Our platform is highly versatile and can be adapted to screen against a wide variety of proteases. This includes commercially available enzymes such as trypsin, chymotrypsin, pepsin, elastase, thrombin, and proteinase K, as well as custom proteases provided by the client or prepared by our team, which may be relevant to specific disease states or applications.

What starting materials do I need to provide?

Typically, the project begins with the amino acid or nucleotide sequence of your protein of interest. From this sequence, our team can handle all subsequent steps, including gene synthesis and the construction of the variant library. Alternatively, if you have an existing DNA library or a purified protein, we can readily incorporate these materials into our workflow.

How is the functional activity of the protein variants maintained during selection for stability?

This is a critical consideration. We can design dual-pressure biopanning strategies. In such a workflow, we alternate selection cycles between a protease challenge and a target-binding step. This ensures that the enriched phage population not only survives the protease treatment but also retains its ability to bind the intended target, thus selecting for variants that are both stable and functional.

What is the typical capacity of the libraries you construct?

We routinely construct phage display libraries with diversities ranging from 10^8 to 10^11 colony-forming units (CFU). This vast diversity ensures comprehensive coverage of the potential sequence space, significantly increasing the probability of identifying variants with the desired stability and functional characteristics.

Beyond identifying resistant sequences, what data will I receive?

You will receive a comprehensive final report that includes all primary data, a detailed description of the methodologies used, the complete sequences of validated monoclonal hits (from Sanger sequencing), and a rich dataset from our NGS analysis detailing the convergence of enriched sequence families. The report will also contain characterization data for lead candidates, such as their protease resistance profile (e.g., IC50) and binding affinity measurements, along with our scientific recommendations for the next steps in your development pipeline.

Protease Stable Protein Domain Variant Screening Service

Introduction Services Workflow Platform Advantages FAQs

The Imperative for Proteolytically Stable Protein Biologics

The therapeutic and diagnostic utility of proteins, including antibodies, enzymes, and engineered scaffolds, is frequently constrained by their susceptibility to proteolytic degradation.

In vivo challenges

Endogenous proteases can drastically reduce a protein’s circulatory half-life and bioavailability, undermining therapeutic efficacy.

Ex vivo challenges

During manufacturing, formulation, and storage, proteolytic cleavage threatens product integrity, stability, and potency.

Fig.1 Protein-enzyme interactions. (Creative Biolabs AI)

Consequently, the development of protein variants with enhanced resistance to specific proteases is a critical objective in protein engineering and drug development.

Phage display technology has emerged as a paramount tool for directed evolution, offering a robust, high-throughput platform for the construction and screening of vast protein variant libraries. By subjecting these libraries to defined selective pressures, Creative Biolabs enable the isolation of rare protein variants that exhibit:

Enhanced proteolytic stability

Retention of intrinsic biological activity

This strategy empowers the prospective engineering of biologics designed to survive and function in challenging proteolytic environments.

Ready to explore your protease-stable variants? Let's talk.

Service for Protease Stability Engineering

Creative Biolabs provides a comprehensive, end-to-end Protease Stable Protein Domain Variant Screening Service, leveraging our state-of-the-art phage display platform. Our service is engineered to identify and optimize protein domains that demonstrate superior resilience against specific proteases.

Protein types covered

Antibody fragments (e.g., scFv, Fab)	Alternative scaffolds
Enzymes	Other binding proteins

Fully customizable screening

Clients can specify target proteases of interest, including:

Common serine proteases (trypsin, chymotrypsin)	Pepsin
Endoproteinase Glu-C	Proteinase K
Other proteases relevant to disease microenvironments or industrial processes

The ultimate deliverable is a suite of validated, protease-stable protein variants, accompanied by a comprehensive data package detailing their sequence, stability profile, and functional characteristics—ready for downstream development and application.

Want to accelerate your protein engineering? Start the conversation now.

The Discovery Pipeline: From Library Construction to Lead Validation

Our service is executed through a meticulously structured and scientifically rigorous workflow, ensuring transparency and optimal outcomes at every stage.

1. Construction of Protein Variant Libraries

The foundation of a successful screening campaign is a high-quality, high-diversity library. Creative Biolabs offers flexible strategies tailored to project needs:

Human Protein Variant Libraries

For projects involving human proteins, we can construct variant libraries based on the native protein sequence. These libraries serve as an excellent resource for isolating variants with enhanced stability profiles while maintaining a human sequence background to minimize immunogenicity.

Customized & Synthetic Libraries

Leveraging client-provided sequences or target profiles, we design and construct large-capacity semi-synthetic or fully synthetic protein libraries. This approach affords maximal control over sequence diversity and allows for the exploration of novel chemical space to identify variants with exceptional protease resistance.

Mutagenesis Libraries

For the optimization of an existing protein, we can generate precisely tailored mutagenesis libraries. This includes targeted mutagenesis of specific sequence regions hypothesized to be protease-sensitive, as well as random mutagenesis libraries (e.g., error-prone PCR) to introduce broad, unbiased diversity across the protein domain.

2. Stability Screening (Proteolytic Biopanning)

This core stage involves the application of selective pressure to enrich for protease-resistant variants.

Controlled protease challenge

The phage display library is exposed to the target protease under precisely regulated conditions (concentration, time, temperature).

Elimination of weak variants

Non-resistant proteins are cleaved and removed via specialized selection gates.

Survival of stable variants

Robust protein domains that withstand the proteolytic challenge are retained and amplified in subsequent rounds of biopanning.

This iterative process progressively enriches the library for the most robust and stable protein variants.

3. Validation & Optimization Following enrichment, a multi-tiered validation process is initiated to identify and characterize the most promising candidates:

Monoclonal Validation

Isolate and characterize individual clones to confirm enhanced protease resistance and retained activity.

Sequence Verification

Confirm candidate identity via Sanger sequencing, with optional NGS to reveal broader variant diversity and guide structure–activity insights.

Lead Optimization

Further engineer top variants to improve activity, specificity, or thermal stability for optimized final candidates.

4. Downstream Protein Characterization & Engineering

Our service extends beyond discovery to include comprehensive support for downstream applications:

Protein Characterization

We provide in-depth analysis of lead variants, including recombinant expression, purification, and biophysical characterization of their structure, stability (e.g., differential scanning fluorimetry), affinity (e.g., SPR, BLI), and functional activity.

Protein Engineering

Promising candidates can be further engineered to meet specific therapeutic or diagnostic criteria. This includes services such as affinity maturation, humanization, and other bespoke modifications designed to maximize clinical or commercial potential.

Looking for tailored screening solutions? We're here to help.

Mechanistic Basis of the Phage Display Selection Platform

Our capacity to deliver superior protease-stable protein variants is built upon a sophisticated and powerful phage display technology platform centered on the M13 bacteriophage.

Advanced Phage Display System

A well-established, robust platform refined over more than a decade of experience.

Robustness of M13

Naturally resistant to incubation with various proteases at defined concentrations while retaining infectivity — a key feature that underpins our screening strategy.

Broad Protease Compatibility

Our platform accommodates a diverse array of proteases for screening.

Tailored Biopanning Protocols

Screening conditions are customized to match the desired stringency and project goals.

High-Sensitivity and High-Throughput

The platform is optimized for screening large libraries to identify rare, high-value candidates efficiently.

Let's design the right strategy for your discovery needs.

Hallmarks of Our Discovery Service

With over a decade of dedicated experience in phage display technology, Creative Biolabs stands as a premier partner for the discovery of protease-stable protein variants.

Deep Scientific Expertise

Our team of seasoned scientists possesses an intimate understanding of protein engineering, phage display, and proteolytic pathways, ensuring the intelligent design and execution of every project.

Unmatched Customization

From library construction to biopanning protocol, We are tailored to the client's specific protein, target protease, and ultimate application.

Integrated, End-to-End Solution

We offer a seamless, one-stop service that guides projects from initial concept to the delivery of fully characterized and engineered lead proteins, saving our clients time and resources.

Cutting-Edge Technology

By integrating our advanced phage display platform with powerful analytical tools like Next-Generation Sequencing, we provide deeper data insights and a higher probability of success.

Contact us today and see how we can support your next breakthrough.

FAQs

Q: What types of proteases can be used in the screening process?
A: Our platform is highly versatile and can be adapted to screen against a wide variety of proteases. This includes commercially available enzymes such as trypsin, chymotrypsin, pepsin, elastase, thrombin, and proteinase K, as well as custom proteases provided by the client or prepared by our team, which may be relevant to specific disease states or applications.
Q: What starting materials do I need to provide?
A: Typically, the project begins with the amino acid or nucleotide sequence of your protein of interest. From this sequence, our team can handle all subsequent steps, including gene synthesis and the construction of the variant library. Alternatively, if you have an existing DNA library or a purified protein, we can readily incorporate these materials into our workflow.
Q: How is the functional activity of the protein variants maintained during selection for stability?
A: This is a critical consideration. We can design dual-pressure biopanning strategies. In such a workflow, we alternate selection cycles between a protease challenge and a target-binding step. This ensures that the enriched phage population not only survives the protease treatment but also retains its ability to bind the intended target, thus selecting for variants that are both stable and functional.
Q: What is the typical capacity of the libraries you construct?
A: We routinely construct phage display libraries with diversities ranging from 10⁸ to 10¹¹ colony-forming units (CFU). This vast diversity ensures comprehensive coverage of the potential sequence space, significantly increasing the probability of identifying variants with the desired stability and functional characteristics.
Q: Beyond identifying resistant sequences, what data will I receive?
A: You will receive a comprehensive final report that includes all primary data, a detailed description of the methodologies used, the complete sequences of validated monoclonal hits (from Sanger sequencing), and a rich dataset from our NGS analysis detailing the convergence of enriched sequence families. The report will also contain characterization data for lead candidates, such as their protease resistance profile (e.g., IC50) and binding affinity measurements, along with our scientific recommendations for the next steps in your development pipeline.

Have a project in mind? Connect with our experts today.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: